The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved:- 1. the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company. 2. an Interim Dividend @ 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved the Scheme of Amalgamation ('Scheme') pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of its wholly owned subsidiaries viz. Auronext Pharma Private Limited and Mviyes Pharma Ventures Private Limited ('Transferor Companies') with Aurobindo Pharma Limited ('Transferee Company'). The Scheme would be subject to the requisite statutory / regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench). We enclose herewith the details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015 in Annexure-A to this letter. We refer to our letter dated August 12, 2021 informing about the approval of the Scheme of Amalgamation by the Board of Director of the Company, providing for the amalgamation of wholly owned subsidiaries of the Company viz., Auronext Pharma Private and Mviyes Pharma Ventures Private Limited with the Company subject to the requisite statutory I regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench). (As Per BSE Announcement Dated on 01/04/2023) Submission of Order of NCLT approving the Scheme of Amalgamation of Mviyes Pharma Ventures Private Limited and Auronext Pharma Private Limited, wholly owned subsidiaries of the Company, with the Company (As Per BSE Announcement Dated on 06.05.2024